Literature DB >> 11939786

Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin.

Laurence Gesquiere1, Wonhwa Cho, Papasani V Subbaiah.   

Abstract

Although many isoforms of secretory phospholipases A(2) (sPLA(2)) are known to be secreted by various inflammatory cells, and are present in plasma, their role in lipoprotein metabolism is unknown. We studied the in vitro hydrolysis of lipoprotein phospholipids by group IIa and group V sPLA(2), two structurally related enzymes with differing phospholipid specificities. The group V sPLA(2) was about 30 times more efficient than the group IIa enzyme in the hydrolysis of lipoprotein phosphatidylcholine (PC), and both enzymes were more active on high density liporotein (HDL) than on low density lipoprotein (LDL). The lower activity on LDL appears to be due to the higher sphingomyelin (SPH) concentration in this lipoprotein. PC hydrolysis in lipoproteins was stimulated significantly by enzymatic depletion of their SPH. The hydrolysis of PC in liposomes was inhibited by the incorporation of SPH, and this inhibition was reversed by treatment with sphingomyelinase. The incorporation of ceramide, on the other hand, stimulated the sPLA(2) activity significantly. Unlike most sPLA(2), which show no fatty acid preference, group V sPLA(2) released disproportionately more linoleate, and less arachidonate from lipoproteins. These studies show that group V sPLA(2) is physiologically more important than group IIa enzyme in lipoprotein metabolism, that the sPLA(2) activities are regulated by sphingomyelin and ceramide, and that the pathological effects of sPLA(2) may not be mediated through stimulation of eicosanoid synthesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939786     DOI: 10.1021/bi015757x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

1.  Protection of membrane cholesterol by sphingomyelin against free radical-mediated oxidation.

Authors:  Robert M Sargis; Papasani V Subbaiah
Journal:  Free Radic Biol Med       Date:  2006-02-28       Impact factor: 7.376

2.  Guanidination of notexin alters its membrane-damaging activity in response to sphingomyelin and cholesterol.

Authors:  Pei-Hsiu Kao; Yi-Ling Chiou; Shinne-Ren Lin; Long-Sen Chang
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

3.  Role of sphingomyelin and ceramide in the regulation of the activity and fatty acid specificity of group V secretory phospholipase A2.

Authors:  Dev K Singh; Laurence R Gesquiere; Papasani V Subbaiah
Journal:  Arch Biochem Biophys       Date:  2006-11-21       Impact factor: 4.013

Review 4.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology.

Authors:  Irena Levitan; Suncica Volkov; Papasani V Subbaiah
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

Review 5.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

6.  Effect of double bond geometry in sphingosine base on the antioxidant function of sphingomyelin.

Authors:  Papasani V Subbaiah; Debajit Sircar; Ravi S Lankalapalli; Robert Bittman
Journal:  Arch Biochem Biophys       Date:  2008-10-12       Impact factor: 4.013

7.  Secretory phospholipase A2 induces dendritic cell maturation.

Authors:  Laure Perrin-Cocon; Sophie Agaugué; Frédéric Coutant; Aurélie Masurel; Sofiane Bezzine; Gérard Lambeau; Patrice André; Vincent Lotteau
Journal:  Eur J Immunol       Date:  2004-08       Impact factor: 5.532

8.  Modulation of the activity of cytosolic phospholipase A2alpha (cPLA2alpha) by cellular sphingolipids and inhibition of cPLA2alpha by sphingomyelin.

Authors:  Hiroyuki Nakamura; Shigeo Wakita; Akiko Suganami; Yutaka Tamura; Kentaro Hanada; Toshihiko Murayama
Journal:  J Lipid Res       Date:  2009-10-16       Impact factor: 5.922

9.  Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL.

Authors:  Boris B Boyanovsky; Preetha Shridas; Michael Simons; Deneys R van der Westhuyzen; Nancy R Webb
Journal:  J Lipid Res       Date:  2008-12-03       Impact factor: 5.922

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.